HiSilicon

Insilico Medicine is a leading clinical-stage biotechnology company that utilizes its proprietary end-to-end artificial intelligence platform, Pharma.AI, to accelerate drug discovery and development. The company's platform integrates generative AI to identify novel biological targets, design molecular structures with specific properties, and predict clinical trial outcomes. Its lead program, ISM001-055, is a potentially first-in-class small molecule inhibitor of TNIK for the treatment of idiopathic pulmonary fibrosis, which has progressed into Phase 2 clinical trials. Insilico Medicine has established significant strategic partnerships with major pharmaceutical companies like Sanofi and Exelixis, while maintaining a robust internal pipeline across oncology, immunology, and fibrosis.